You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Syapse continues to help the FDA Oncology Center of Excellence incorporate real-world data into the regulatory decision-making process.
The data collected could improve understanding of drug efficacy, deliver precision cancer care, guide clinical trial matching, and advance research projects.
Including the new round, the maker of software to support precision oncology care and drug discovery has landed nearly $100 million in equity investments to date.
The companies had agreed in early 2018 to collaborate on the development of technologies to support precision oncology initiatives, but Roche said "priorities" have changed.
The FDA center of excellence has engaged the technology vendor to incorporate real-world evidence into regulatory decision-making for precision oncology treatments.
The company has signed a new, multiyear agreement with the Korean health system to build a data sharing network to support precision cancer care in East Asia.
At a real-world data workshop, Wendy Rubinstein said that labs have a responsibility under the 21st Century Cures Act to facilitate integration of genomic data into EHRs.
The partners will glean real-world evidence from Syapse's network of health system partners with the aim of informing precision oncology approaches and advancing research.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.